PMID- 32104189
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2020
DP  - 2020
TI  - Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary 
      Fibrosis: A Meta-Analysis.
PG  - 1752387
LID - 10.1155/2020/1752387 [doi]
LID - 1752387
AB  - OBJECTIVE: To evaluate the efficacy and safety of traditional Chinese medicine 
      (TCM) on lung function and quality of life of idiopathic pulmonary fibrosis (IPF) 
      patients by meta-analysis. METHODS: Randomized controlled trials (RCTs) related 
      to TCM and IPF were searched on PubMed, EMBASE Cochrane Library, ClinicalTrials, 
      China National Knowledge Infrastructure (CNKI), Wanfang Database, Chin VIP 
      Information (VIP), and Chinese Biomedical Database (CBM) until December 2018. 
      Standard mean difference (SMD) and 95% CI were calculated for the measurements 
      related to lung function (FEV1/FVC, FVC%, FEV1%, TLC%, DLCO% or DLCO, and VC%) 
      and other parameters (PO2, 6MWD, and SGRQ) when comparing TCM treatment to the 
      control group. Relative risk (RR) and 95% CI of adverse events (AEs) were 
      calculated to assess the safety of TCM. RESULTS: A total of 40 RCTs comparing TCM 
      to western medicine (WM) and involving 3194 IPF patients were eligible for the 
      meta-analysis. The pooled results showed that TCM treatment improved 
      significantly PO2 (SMD = 0.80, 95% CI 0.54 to 1.06, p < 0.001), FEV1% 
      (SMD = 0.57, 95% CI 0.42 to 0.71, p < 0.001), DLCO% (SMD = 0.38, 95% CI 0.28 to 
      0.48, p < 0.001), 6MWD (SMD = 0.70, 95% CI 0.56 to 0.84, p < 0.001) and other 
      measurements and reduced SGRQ scores (SMD = -0.51, 95% CI -0.70 to -0.22, p < 
      0.001). Subgroup analysis of different study durations (3 months, >/= 6 months) and 
      comparison models (TCM vs. WM, TCM + WM vs. WM or TCM vs. placebo) showed similar 
      results. No significant difference of risk of AEs was observed between both 
      groups (RR = 0.66, 95% CI: 0.27-1.60, p=0.352). There was no obvious publication 
      bias, and the pooled results were stable according to sensitivity analysis. 
      CONCLUSION: To the best of our knowledge, the present study had the largest 
      sample size. Our results indicated that TCM treatment may help provide benefit to 
      the lung function, exercise capacity, and quality of life of IPF patients, alone 
      or combined with WM, when compared to WM. More rigorous RCTs were needed in the 
      future.
CI  - Copyright (c) 2020 Kun Ji et al.
FAU - Ji, Kun
AU  - Ji K
AUID- ORCID: 0000-0001-7659-1677
AD  - Department of Respiratory Medicine, Dongfang Hospital, Beijing University of 
      Traditional Chinese Medicine, Beijing 100078, China.
FAU - Ma, Jianling
AU  - Ma J
AUID- ORCID: 0000-0002-3701-7215
AD  - Department of Respiratory Medicine, Dongfang Hospital, Beijing University of 
      Traditional Chinese Medicine, Beijing 100078, China.
FAU - Wang, Liangmin
AU  - Wang L
AUID- ORCID: 0000-0003-1928-5205
AD  - Department of Respiratory Medicine, Dongfang Hospital, Beijing University of 
      Traditional Chinese Medicine, Beijing 100078, China.
FAU - Li, Niuniu
AU  - Li N
AUID- ORCID: 0000-0003-0661-7637
AD  - Department of Respiratory Medicine, Dongfang Hospital, Beijing University of 
      Traditional Chinese Medicine, Beijing 100078, China.
FAU - Dong, Shangjuan
AU  - Dong S
AUID- ORCID: 0000-0001-5216-9324
AD  - Department of Respiratory Medicine, Dongfang Hospital, Beijing University of 
      Traditional Chinese Medicine, Beijing 100078, China.
FAU - Shi, Liqing
AU  - Shi L
AUID- ORCID: 0000-0002-6808-4808
AD  - Department of Respiratory Medicine, Dongfang Hospital, Beijing University of 
      Traditional Chinese Medicine, Beijing 100078, China.
LA  - eng
PT  - Journal Article
DEP - 20200212
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC7040417
COIS- All authors declare no conflicts of interest.
EDAT- 2020/02/28 06:00
MHDA- 2020/02/28 06:01
PMCR- 2020/02/13
CRDT- 2020/02/28 06:00
PHST- 2019/08/23 00:00 [received]
PHST- 2019/12/03 00:00 [revised]
PHST- 2019/12/20 00:00 [accepted]
PHST- 2020/02/28 06:00 [entrez]
PHST- 2020/02/28 06:00 [pubmed]
PHST- 2020/02/28 06:01 [medline]
PHST- 2020/02/13 00:00 [pmc-release]
AID - 10.1155/2020/1752387 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2020 Feb 12;2020:1752387. doi: 
      10.1155/2020/1752387. eCollection 2020.